Genelux CORP 10-Q quarterly reports

Genelux Corporation's Q2 2026 Form 10-Q filing reveals continued net losses and substantial doubt about its ability to continue as a going concern, despite increased R&D spending.

Genelux Corporation reported increased net losses and cash burn in Q3 2025, with existing capital projected to fund operations only into the third quarter of 2026, raising substantial doubt about its going concern ability.

Genelux Corporation reported increased net losses and a going concern warning, despite progress in clinical trials and a recent $9.6 million capital raise.

Genelux Corporation reports a net loss of $7.5 million for Q1 2025, but extends its cash runway into the third quarter of 2026 following a public offering.

Genelux Corporation's third quarter 2024 report shows a net loss of $6.467 million, with ongoing clinical trial advancements and a cash runway extended into the first quarter of 2026.

Genelux Corporation's second quarter 2024 results show a net loss of $14.4 million, but the company's cash runway is extended into the first quarter of 2026 due to recent public offerings.

Genelux Corporation announced its financial results for the first quarter of 2024, highlighting a net loss of $7.85 million and ongoing clinical trial activities.